ASND · Ascendis Pharma A/S
$253.29
-1.52 (-0.60%)
At close · Aug 21
Market Cap
$16.71B
Shares
65.59M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$253.29
Open$253.62
Day$252.87–257.89
52W close$189.74–277.18
Avg vol 30d526K
Short int3.4M · 5.2% float · 7.2d
Short vol68%
Last earningsAug 13, 2026
DataJan 2020–Aug 2026
Up next
Next earnings call
Nov 16, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Moderate
Market backdrop
VIX 15.1 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+10%
above
Price vs 50-day avg
+0%
above
RSI (14)
51
neutral
MACD trend
Positive
52-week position
73%
mid-range
Momentum
relative strength
1-month return
0%
trailing
6-month return
+5%
trailing
YTD return
+19%
this year
Relative strength
−7%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $252 › 200d $230 — 50d above 200d
Institutional flow
Accumulating
+9% holders QoQ · +82 funds added
Insider flow
Accumulating
Net +$777.1K over 90 days · 0% sells
Short interest
Rising
5.19% of float · ▲ +9.7% MoM · 7.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
309 holders — near 3-yr high, broad support
Squeeze score
67
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
37%
annualized · 1-yr
Max drawdown
−18%
past year
ATR
3.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+10%
Bullish
Price vs 50-day avg
+0%
Bullish
RSI (14)
51
Neutral
MACD trend
Positive
Bullish
52-week position
73%
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $252 › 200d $230 — 50d above 200d
Institutional flow
Accumulating
+9% holders QoQ · +82 funds added
Insider flow
Accumulating
Net +$777.1K over 90 days · 0% sells
Short interest
Rising
5.19% of float · ▲ +9.7% MoM · 7.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
309 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $190
Now $253 · 73%
Range high $277
vs 200-day avg +10%
vs 50-day avg +0%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ASND
this stock
Ascendis Pharma A/S
|
$16.71B | +18.8% | — | — | 5.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +20.9% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.87B | +8.1% | +20.8% | 20.7 | 3.3% |
|
ARGX
Argenx SE
|
$64.56B | +23.6% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$58.31B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ASND | +1.9% | -0.2% | +4.6% | +3.9% | +18.8% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +3.3% | -3.9% | -6.9% | +1.4% | +6.5% |
Key facts
CIK
1612042
CUSIP
K08588103
13F (30d)
295 filings
290 filers
Visit website
Investor relations